Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2022-03-07 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Février 2022 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers". This explicitly indicates a monthly disclosure regarding the total number of voting rights and shares, which is a regulatory requirement in France (AMF). This type of filing, detailing share structure and voting rights, is not explicitly covered by the primary definitions (like 10-K, ER, IR). However, it is a specific regulatory disclosure. Reviewing the definitions, none perfectly match this specific monthly voting rights report. It is a mandatory regulatory filing that doesn't fit into the specific categories like Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't fit the other specific types.
2022-03-07 French
bioMérieux – 2021 Financial Results
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – 2021 Financial Results" and contains detailed financial tables, key performance indicators (KPIs) for the full year 2021 (sales, operating income, net income), forward-looking guidance for 2022, and analysis broken down by application and region. The text explicitly mentions that the Board of Directors approved the audited consolidated financial statements for the year ending December 31, 2021. This content structure—full-year financial performance summary, detailed segment breakdowns, and management commentary—is characteristic of an Earnings Release (ER) or a comprehensive Annual Report (10-K). Given that it summarizes the results and provides guidance immediately following the close of the fiscal year (March 2, 2022, for FY 2021), it functions primarily as the initial announcement of the full-year results. While it contains substantial detail, it is presented as a press release summarizing the audited results, which aligns best with the 'Earnings Release' (ER) definition, which covers periodical financial results highlights and context. It is not the full, formal 10-K filing itself, but the announcement preceding or accompanying it. The length (over 53k characters) suggests it is more than just highlights, but the format strongly suggests an ER/Press Release announcing the annual figures. FY 2021
2022-03-02 English
bioMérieux – Résultats annuels au 31 décembre 2021
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Résultats annuels au 31 décembre 2021" (Annual Results as of December 31, 2021). It contains detailed financial tables covering revenue, operating income, and net income for the full year 2021 compared to 2020. It also includes management commentary, forward-looking guidance for 2022, and detailed breakdowns by application and region. The text explicitly states that the Board of Directors "a arrêté les comptes consolidés audités du Groupe au 31 décembre 2021" (approved the audited consolidated accounts of the Group as of December 31, 2021). This content structure—comprehensive annual financial performance review, audited figures, and forward guidance—is characteristic of a full Annual Report, which corresponds to the 10-K filing type in the US context, or the primary annual financial disclosure document. FY 2021
2022-03-02 French
MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new mobile application, MYACUTECASETM, by bioMérieux. It details the features, target users (clinicians), and the specific diagnostic tests it supports. It includes quotes from executives and standard 'About Us' and 'Contact' sections typical of corporate news releases. This type of announcement, which is not a formal regulatory filing (like 10-K, IR, or ER) but rather a product/service update intended for the public and investors, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a general 'Investor Presentation' (IP) if it were structured as a slide deck, but given the press release format, RNS is the most appropriate fallback for non-standard corporate news that isn't explicitly defined elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a specific financial filing.
2022-02-17 English
MYACUTECASE™, une application mobile gratuite de bioMérieux pour accompagner les cliniciens dans la prise de décision et le suivi des patients grâce au diagnostic, aux urgences et en soins intensifs
Regulatory Filings Classification · 95% confidence The document is a press release dated February 17, 2022, announcing the launch of a new mobile application, MYACUTECASETM, by bioMérieux. It details the features, target users (clinicians in emergency/intensive care), and the medical context of the application. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about a new product/service offering, which falls under general corporate news. Since there is no specific category for 'Product Launch Announcement' and it is not a standard financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS) for general corporate announcements that don't fit elsewhere, although 'LTR' (Legal Proceedings Report) or 'IR' (Interim Report) are clearly incorrect. Given the context of a major product launch announcement, RNS serves as the best fit among the provided options for non-financial, non-governance specific news.
2022-02-17 French
Janvier 2022 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des marchés financiers" (Monthly information relating to the total number of voting rights and shares provided for by Article L. 233-8 II of the Commercial Code and Article 223-16 of the General Regulation of the AMF). This structure, providing a monthly update on the total number of shares and voting rights as of a specific date (31/01/2022), is characteristic of regulatory filings concerning share capital structure and voting rights, often required under French market regulations. This specific disclosure aligns best with a general regulatory filing or a specific capital/share structure update. Given the options, it is a mandatory regulatory disclosure related to share capital and voting rights. While it touches upon share structure (SHA), the primary focus is the mandatory monthly disclosure of voting rights, which is a specific type of regulatory filing. Since there isn't a dedicated 'Voting Rights Disclosure' code, and it's a mandatory regulatory report, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, since it's a recurring, mandatory disclosure about the *current* state of voting rights rather than an issuance or change event, RNS is the most appropriate general regulatory fallback category for such specific, non-standard reports, although it is highly specific. Given the content is a direct regulatory disclosure about voting rights, RNS (Regulatory Filings) is the most suitable general classification.
2022-02-03 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.